Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

POTASSIUM\RIBOFLAVIN 5^-PHOSPHATE: Who Reports Side Effects? Age, Gender & Country Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Gender Distribution

61.5%
Female
38.5%
Male

Age Information

The average age of patients reporting adverse events with POTASSIUM\RIBOFLAVIN 5^-PHOSPHATE is 79.6 years.

Geographic Distribution

The majority of adverse event reports for POTASSIUM\RIBOFLAVIN 5^-PHOSPHATE originate from PL.

Report Summary & Outcomes

12
Total Reports
12
As Primary/Secondary Suspect
5
Deaths Reported
9
Hospitalizations
2
Life-Threatening
7
Disabilities

Reporting Timeline

First adverse event report: 20200601. Most recent report: 20210605. View full timeline →

More About POTASSIUM\RIBOFLAVIN 5^-PHOSPHATE

POTASSIUM\RIBOFLAVIN 5^-PHOSPHATE Full Profile Reports by Year Drug Interactions